Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 13/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 7/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20863643 | 0.82 | CACNA1H (0.37) | CACNA1HCACNA1CCACNA1GCACNA1BNPBWR1 | |
| SCHEMBL10284433 | 0.80 | KIF11 (0.47) | NPBWR1SCN10A | |
| SCHEMBL10284440 | 0.73 | CACNA1H (0.63) | CACNA1HCACNA1CCACNA1GCACNA1B | |
| SCHEMBL5681855 | 0.70 | NPSR1 (0.59) | NPBWR1 | |
| SCHEMBL846855 | 0.70 | SCN10A (0.58) | SCN10A | |
| SCHEMBL13896660 | 0.70 | SCN10A (0.44) | SCN10A | |
| SCHEMBL13483956 | 0.69 | NPSR1 (0.54) | SCN10A | |
| SCHEMBL14336639 | 0.69 | KCNH2 (0.62) | NPBWR1SCN10A | |
| SCHEMBL10248217 | 0.68 | CACNA1H (0.46) | CACNA1HCACNA1CCACNA1GCACNA1B | |
| SCHEMBL12402382 | 0.67 | SCN10A (0.51) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670463-B2 | Inhibition and enhancement of reprogramming by chromatin modifying enzymes | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | CACNA1H 4678/4885CACNA1C 4692/4885CACNA1G 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.